Sessa Capital invested $175.8 million in Sotera Health by purchasing 10.6 million shares in Q4, bringing its total stake to 20.55 million shares valued at $362.5 million. Despite a 21% stock decline, the investment signals confidence in the company's fundamentals, which include $1.2 billion in revenue and steady 20-year growth, though the stock faces headwinds from litigation risks, high leverage, and a recent secondary offering that flooded the market with shares.

Sotera Health Company announced the appointment of Kenneth D. Krause, Executive Vice President and CFO of Rollins, Inc., as a new independent director to its Board of Directors. Krause brings over 10 years of public company CFO experience and expertise in corporate strategy and capital allocation. Simultaneously, Constantine S. Mihas resigned from the Board effective March 16, 2026, due to a reduction in stockholder-designated director positions.

MIG Capital sold $37.41 million worth of Sotera Health shares (2.26 million shares) in Q4 2025, reducing its stake to 5.88% of AUM. Despite the trim, the fund maintains a significant position in the sterilization and lab testing company. Sotera posted its 20th consecutive year of revenue growth with 5.7% sales increase to $1.16 billion in 2025, while net income nearly doubled to $78 million. The company projects 5-6.5% revenue growth for 2026.

Sotera Health Company announced a secondary offering of 25 million shares of common stock being sold by affiliates of Warburg Pincus and GTCR. The company will not receive proceeds from the offering but will cover offering expenses. Wells Fargo Securities is acting as the underwriter.

Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.

Warburg Pincus, a major shareholder and board member of Sotera Health, sold 9.7 million shares (22.18% of its indirect stake) for $158.7 million on December 3, 2025, at $16.33 per share. Despite the insider selling, Warburg Pincus retains over 34 million shares in the sterilization and lab services company, which has shown strong performance with 31.25% year-over-year growth and consistent earnings growth.

Darsana Capital initiated a new $189 million stake in Wingstop, purchasing 750,000 shares representing 4.45% of their portfolio. Despite recent same-store sales declines, the investment suggests potential long-term growth in the restaurant chain.

Sotera Health Company, a global provider of sterilization solutions and lab services, has appointed Vincent K. Petrella as its new Lead Independent Director, effective January 2, 2025. Petrella, who has served on the company's board since 2020, brings extensive public company leadership experience and will serve as a key liaison between the board, management, and shareholders.

Sotera Health, a leading global provider of sterilization solutions and lab testing services, will hold an Investor Day in New York City to discuss its strategic positioning and future growth plans, including a long-term financial outlook and a 2025-2027 financial plan.

The pharmaceutical sterility testing market is growing rapidly due to increasing demand for safe and effective pharmaceutical products, advancements in testing technologies, and the rising focus on biopharmaceuticals. The market is expected to reach $3.79 billion by 2032, driven by stringent regulations, the need for sterility testing in new therapies, and the shift towards in-house testing.

Sotera Health Company announced a secondary offering of 25,000,000 shares of its common stock, with all shares being offered by certain affiliates of Warburg Pincus and GTCR as selling stockholders. The company will not receive any proceeds from the offering.

Sotera Health Company, a global provider of sterilization solutions and lab services, announced plans to release its Q2 2024 financial results on August 5, 2024, followed by a conference call with management.